Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Aug 2015

Wojtowicz Karolina, Januchowski Radosław, Nowicki Michał, Zabel Maciej

Abstract excerpt

BACKGROUND: Multidrug resistance proteins are one of the most important factors that cause chemotherapy resistance, which in turn reduces therapeutic efficacy and survival for cancer patients. Tunicamycin is one of the most well-known inhibitors of N-glycosylation and is considered a powerful adjunct that can increase the effectiveness of many drugs. Tunicamycin blocks the first step of P-gp (glycoprotein P) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Drug Resistance, Multiple

Share to Glycosylation

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Tunicamycin

Source

Identifiers

PMID: 26349962
DOI: 10.1016/j.biopha.2015.07.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.PMID 26349962Read ↗

Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.Semantic proximity Read ↗

Overexpression of GRP78/BiP in P-Glycoprotein-Positive L1210 Cells is Responsible for Altered Response of Cells to Tunicamycin as a Stressor of the Endoplasmic ReticulumSemantic proximity Read ↗

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Identification of chemoresistance-related cell-surface glycoproteins in leukemia cells and functional validation of candidate glycoproteins.Semantic proximity Read ↗

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expressionSemantic proximity Read ↗

New Insight into P-Glycoprotein as a Drug TargetSemantic proximity Read ↗

Functional roles of glycogene and N‐glycan in multidrug resistance of human breast cancer cellsSemantic proximity Read ↗

Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance.Semantic proximity Read ↗

New Insight into P-Glycoprotein as a Drug TargetSemantic proximity Read ↗

Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variantsSemantic proximity Read ↗

Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signalingSemantic proximity Read ↗

Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.